Please Wait.....
Report
Europe Uterine Cancer Diagnostics Market - Industry Trends and Forecast to 2030
Market Report I 2023-01-01 I 476 Pages I Data Bridge Market Research
Europe uterine cancer diagnostics market is projected to register a CAGR of 10.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation:
Europe Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based and Procedure Based), Type (Endometrial Cancer and Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centres, Cancer Research Centre, Ambulatory Surgical Centres, Specialized Clinics, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others), Country (Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe) Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the Europe uterine cancer diagnostics market are:
- Increasing uterine cancer patients among the women population
- Rise in technological advancement for uterine cancer diagnosis
Market Players
Some of the key market players operating in the Europe uterine cancer diagnostics market are:
- F-Hoffmann La Roche Ltd.
- Siemens Healthcare Private Limited
- ESAOTE SPA
- Olympus Corporation
- Integra LifeSciences
- KARL STORZ SE & Co. KG
- Stryker
- General Electric Company
- FUJIFILM Corporation
- Koninklijke Philips N.V.
- B. Braun SE
- Arquer Diagnostics Ltd
- Surtex Instruments Limited
- GRAIL
TABLE OF CONTENTS
1 INTRODUCTION 118
1.1 OBJECTIVES OF THE STUDY 118
1.2 MARKET DEFINITION 118
1.3 OVERVIEW OF THE EUROPE UTERINE CANCER DIAGNOSTIC MARKET 118
1.4 CURRENCY AND PRICING 120
1.5 LIMITATIONS 120
1.6 MARKETS COVERED 120
2 MARKET SEGMENTATION 128
2.1 MARKETS COVERED 128
2.2 GEOGRAPHICAL SCOPE 129
2.3 YEARS CONSIDERED FOR THE STUDY 130
2.4 DBMR TRIPOD DATA VALIDATION MODEL 131
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.6 MULTIVARIATE MODELLING 135
2.7 MARKET APPLICATION COVERAGE GRID 136
2.8 INSTRUMENT BASED LIFELINE CURVE 137
2.9 DBMR MARKET POSITION GRID 138
2.10 VENDOR SHARE ANALYSIS 140
2.11 SECONDARY SOURCES 141
2.12 ASSUMPTIONS 141
3 EXECUTIVE SUMMARY 142
4 PREMIUM INSIGHTS 145
4.1 PESTEL ANALYSIS 146
4.2 PORTER'S FIVE FORCES 147
4.3 PATENT ANALYSIS OF EUROPE UTERINE CANCER DIAGNOSTICS MARKET 148
4.4 REIMBURSEMENT SCENARIO 149
4.5 INDUSTRY INSIGHTS: 150
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 150
4.7 PRICING STRATEGIES 150
4.8 CONCLUSION 151
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER 152
4.10 COST OF UTERINE CANCER PROCEDURE 154
5 REGULATORY FRAMEWORK 155
6 MARKET OVERVIEW 157
6.1 DRIVERS 159
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS 159
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES 159
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER 160
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH 160
6.2 RESTRAINTS 161
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS 161
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER 161
6.3 OPPORTUNITIES 162
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER 162
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE 162
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS 163
6.4 CHALLENGES 163
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE 163
6.4.2 HIGH COST OF IMAGING SYSTEMS 164
7 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE 165
7.1 OVERVIEW 166
7.2 INSTRUMENT-BASED 169
7.2.1 ULTRASOUND SCANNING 170
7.2.1.1 SYSTEMS 170
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING 171
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING 171
7.2.1.4 ACCESSORIES 171
7.2.2 IMAGING DEVICES 171
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN 172
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI) 172
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN 172
7.2.2.4 OTHERS 172
7.2.3 TESTS 173
7.2.3.1 BLOOD TESTS 173
7.2.3.1.1 COMPLETE BLOOD COUNT 173
7.2.3.1.2 CA125 MARKER BLOOD TEST 173
7.2.3.2 URINE TESTS 174
7.2.3.3 OTHER TESTS 174
7.2.4 OTHERS 174
7.3 PROCEDURE BASED 174
7.3.1 ENDOMETRIAL BIOPSY 175
7.3.2 HYSTEROSCOPY 175
7.3.3 DILATION & CURETTAGE 175
7.3.4 CYSTOSCOPY 175
7.3.5 PROCTOSCOPY 176
7.3.6 OTHERS 176
8 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE 177
8.1 OVERVIEW 178
8.2 ENDOMETRIAL CANCER 181
8.2.1 SEROUS ADENOCARCINOMA 182
8.2.1.1 INSTRUMENT-BASED 182
8.2.1.1.1 ULTRASOUND SCANNING 183
8.2.1.1.2 IMAGING DEVICES 183
8.2.1.1.3 TESTS 183
8.2.1.1.4 OTHERS 183
8.2.1.2 PROCEDURE-BASED 184
8.2.1.2.1 ENDOMETRIAL BIOPSY 184
8.2.1.2.2 HYSTEROSCOPY 184
8.2.1.2.3 DILATION & CURETTAGE 184
8.2.1.2.4 CYSTOSCOPY 184
8.2.1.2.5 PROCTOSCOPY 184
8.2.1.2.6 OTHERS 185
8.2.2 ADENOSQUAMOUS CARCINOMA 185
8.2.2.1 INSTRUMENT-BASED 185
8.2.2.1.1 ULTRASOUND SCANNING 185
8.2.2.1.2 IMAGING DEVICES 186
8.2.2.1.3 TESTS 186
8.2.2.1.4 OTHERS 186
8.2.2.2 PROCEDURE-BASED 186
8.2.2.2.1 ENDOMETRIAL BIOPSY 186
8.2.2.2.2 HYSTEROSCOPY 186
8.2.2.2.3 DILATION & CURETTAGE 187
8.2.2.2.4 CYSTOSCOPY 187
8.2.2.2.5 PROCTOSCOPY 187
8.2.2.2.6 OTHERS 187
8.2.3 UTERINE CARCINOSARCOMA 187
8.2.3.1 INSTRUMENT-BASED 187
8.2.3.1.1 ULTRASOUND SCANNING 188
8.2.3.1.2 IMAGING DEVICES 188
8.2.3.1.3 TESTS 188
8.2.3.1.4 OTHERS 188
8.2.3.2 PROCEDURE-BASED 189
8.2.3.2.1 ENDOMETRIAL BIOPSY 189
8.2.3.2.2 HYSTEROSCOPY 189
8.2.3.2.3 DILATION & CURETTAGE 189
8.2.3.2.4 CYSTOSCOPY 189
8.2.3.2.5 PROCTOSCOPY 189
8.2.3.2.6 OTHERS 190
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM 190
8.2.4.1 INSTRUMENT-BASED 190
8.2.4.1.1 ULTRASOUND SCANNING 190
8.2.4.1.2 IMAGING DEVICES 191
8.2.4.1.3 TESTS 191
8.2.4.1.4 OTHERS 191
8.2.4.2 PROCEDURE-BASED 191
8.2.4.2.1 ENDOMETRIAL BIOPSY 191
8.2.4.2.2 HYSTEROSCOPY 191
8.2.4.2.3 DILATION & CURETTAGE 192
8.2.4.2.4 CYSTOSCOPY 192
8.2.4.2.5 PROCTOSCOPY 192
8.2.4.2.6 OTHERS 192
8.3 UTERINE SARCOMA 192
8.3.1 LEIOMYOSARCOMA 193
8.3.1.1 INSTRUMENT-BASED 193
8.3.1.1.1 ULTRASOUND SCANNING 194
8.3.1.1.2 IMAGING DEVICES 194
8.3.1.1.3 TESTS 194
8.3.1.1.4 OTHERS 194
8.3.1.2 PROCEDURE-BASED 195
8.3.1.2.1 ENDOMETRIAL BIOPSY 195
8.3.1.2.2 HYSTEROSCOPY 195
8.3.1.2.3 DILATION & CURETTAGE 195
8.3.1.2.4 CYSTOSCOPY 195
8.3.1.2.5 PROCTOSCOPY 195
8.3.1.2.6 OTHERS 196
8.3.2 ENDOMETRIAL STROMAL SARCOMA 196
8.3.2.1 INSTRUMENT-BASED 196
8.3.2.1.1 ULTRASOUND SCANNING 196
8.3.2.1.2 IMAGING DEVICES 197
8.3.2.1.3 TESTS 197
8.3.2.1.4 OTHERS 197
8.3.2.2 PROCEDURE-BASED 197
8.3.2.2.1 ENDOMETRIAL BIOPSY 197
8.3.2.2.2 HYSTEROSCOPY 197
8.3.2.2.3 DILATION & CURETTAGE 198
8.3.2.2.4 CYSTOSCOPY 198
8.3.2.2.5 PROCTOSCOPY 198
8.3.2.2.6 OTHERS 198
8.3.3 UNDIFFERENTIATED SARCOMA 198
8.3.3.1 INSTRUMENT-BASED 199
8.3.3.1.1 ULTRASOUND SCANNING 199
8.3.3.1.2 IMAGING DEVICES 199
8.3.3.1.3 TESTS 199
8.3.3.1.4 OTHERS 199
8.3.3.2 PROCEDURE-BASED 200
8.3.3.2.1 ENDOMETRIAL BIOPSY 200
8.3.3.2.2 HYSTEROSCOPY 200
8.3.3.2.3 DILATION & CURETTAGE 200
8.3.3.2.4 CYSTOSCOPY 200
8.3.3.2.5 PROCTOSCOPY 201
8.3.3.2.6 OTHERS 201
9 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP 202
9.1 OVERVIEW 203
9.2 >60 YEARS 206
9.3 51-60 YEARS 207
9.4 41-50 YEARS 208
9.5 31-40 YEARS 209
9.6 <30 YEARS 210
10 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY END USER 211
10.1 OVERVIEW 212
10.2 HOSPITALS 215
10.3 DIAGNOSTIC CENTERS 216
10.4 CANCER RESEARCH CENTERS 217
10.5 AMBULATORY SURGICAL CENTERS 218
10.6 SPECIALIZED CLINICS 219
10.7 OTHERS 220
11 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 221
11.1 OVERVIEW 222
11.2 DIRECT TENDER 225
11.3 THIRD PARTY DISTRIBUTORS 226
11.4 OTHERS 227
12 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, BY REGION 228
12.1 EUROPE 229
12.1.1 GERMANY 245
12.1.2 FRANCE 256
12.1.3 UNITED KINGDOM 268
12.1.4 ITALY 281
12.1.5 SPAIN 293
12.1.6 RUSSIA 304
12.1.7 NETHERLANDS 317
12.1.8 POLAND 330
12.1.9 SWITZERLAND 343
12.1.10 BELGIUM 356
12.1.11 SWEDEN 369
12.1.12 NORWAY 382
12.1.13 DENMARK 395
12.1.14 FINLAND 408
12.1.15 TURKEY 421
12.1.16 REST OF EUROPE 434
13 EUROPE UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 435
13.1 COMPANY SHARE ANALYSIS: EUROPE 435
14 SWOT ANALYSIS 436
15 COMPANY PROFILE 437
15.1 KONINKLIJKE PHILIPS N.V. 437
15.1.1 COMPANY SNAPSHOT 437
15.1.2 REVENUE ANALYSIS 437
15.1.3 COMPANY SHARE ANALYSIS 438
15.1.4 PRODUCT PORTFOLIO 438
15.1.5 RECENT DEVELOPMENTS 438
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED. 440
15.2.1 COMPANY SNAPSHOT 440
15.2.2 COMPANY SHARE ANALYSIS 440
15.2.3 PRODUCT PORTFOLIO 441
15.2.4 RECENT DEVELOPMENTS 441
15.3 GENERAL ELECTRIC COMPANY 442
15.3.1 COMPANY SNAPSHOT 442
15.3.2 REVENUE ANALYSIS 442
15.3.3 COMPANY SHARE ANALYSIS 443
15.3.4 PRODUCT PORTFOLIO 443
15.3.5 RECENT DEVELOPMENTS 443
15.4 SIEMENS HEALTHCARE GMBH 445
15.4.1 COMPANY SNAPSHOT 445
15.4.2 REVENUE ANALYSIS 445
15.4.3 COMPANY SHARE ANALYSIS 446
15.4.4 PRODUCT PORTFOLIO 446
15.4.5 RECENT DEVELOPMENTS 446
15.5 FUJIFILM CORPORATION 447
15.5.1 COMPANY SNAPSHOT 447
15.5.2 REVENUE ANALYSIS 447
15.5.3 COMPANY SHARE ANALYSIS 448
15.5.4 PRODUCT PORTFOLIO 448
15.5.5 RECENT DEVELOPMENTS 448
15.6 AED.MD 450
15.6.1 COMPANY SNAPSHOT 450
15.6.2 PRODUCT PORTFOLIO 450
15.6.3 RECENT DEVELOPMENTS 450
15.7 ARQUER DIAGNOSTICS LTD 451
15.7.1 COMPANY SNAPSHOT 451
15.7.2 PRODUCT PORTFOLIO 451
15.7.3 RECENT DEVELOPMENTS 451
15.8 B. BRAUN SE 452
15.8.1 COMPANY SNAPSHOT 452
15.8.2 PRODUCT PORTFOLIO 452
15.8.3 RECENT DEVELOPMENTS 452
15.9 ESAOTE SPA 453
15.9.1 COMPANY SNAPSHOT 453
15.9.2 PRODUCT PORTFOLIO 453
15.9.3 RECENT DEVELOPMENTS 453
15.10 F. HOFFMANN-LA ROCHE LTD 455
15.10.1 COMPANY SNAPSHOT 455
15.10.2 REVENUE ANALYSIS 455
15.10.3 PRODUCT PORTFOLIO 456
15.10.4 RECENT DEVELOPMENTS 456
15.11 GRAIL 457
15.11.1 COMPANY SNAPSHOT 457
15.11.2 PRODUCT PORTFOLIO 457
15.11.3 RECENT DEVELOPMENTS 457
15.12 GUZIP BIOMARKERS CORPORATION 459
15.12.1 COMPANY SNAPSHOT 459
15.12.2 PRODUCT PORTFOLIO 459
15.12.3 RECENT DEVELOPMENTS 459
15.13 INTEGRA LIFESCIENCES 460
15.13.1 COMPANY SNAPSHOT 460
15.13.2 REVENUE ANALYSIS 460
15.13.3 PRODUCT PORTFOLIO 461
15.13.4 RECENT DEVELOPMENTS 461
15.14 JALAL SURGICAL 462
15.14.1 COMPANY SNAPSHOT 462
15.14.2 PRODUCT PORTFOLIO 462
15.14.3 RECENT DEVELOPMENTS 462
15.15 KARL STORZ SE & CO. KG 463
15.15.1 COMPANY SNAPSHOT 463
15.15.2 PRODUCT PORTFOLIO 463
15.15.3 RECENT DEVELOPMENTS 464
15.16 MEDTRONIC 465
15.16.1 COMPANY SNAPSHOT 465
15.16.2 REVENUE ANALYSIS 465
15.16.3 PRODUCT PORTFOLIO 466
15.16.4 RECENT DEVELOPMENTS 466
15.17 NARANG MEDICAL LIMITED 467
15.17.1 COMPANY SNAPSHOT 467
15.17.2 PRODUCT PORTFOLIO 467
15.17.3 RECENT DEVELOPMENTS 467
15.18 OLYMPUS CORPORATION 468
15.18.1 COMPANY SNAPSHOT 468
15.18.2 REVENUE ANALYSIS 468
15.18.3 PRODUCT PORTFOLIO 469
15.18.4 RECENT DEVELOPMENTS 469
15.19 STRYKER 470
15.19.1 COMPANY SNAPSHOT 470
15.19.2 REVENUE ANALYSIS 470
15.19.3 PRODUCT PORTFOLIO 471
15.19.4 RECENT DEVELOPMENTS 471
15.20 SURTEX INSTRUMENTS LIMITED. 472
15.20.1 COMPANY SNAPSHOT 472
15.20.2 PRODUCT PORTFOLIO 472
15.20.3 RECENT DEVELOPMENTS 472
16 QUESTIONNAIRE 473
17 RELATED REPORTS 476
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security